SAWAI PHARMACEUTICAL CO., LTD. Inactive Instrument
Sawai Pharmaceutical Co., Ltd. Share Price Japan Exchange
Equities
4555
JP3323050009
Pharmaceuticals
| Sales 2024 * | 194B 1.22B 97.83B | Sales 2025 * | 203B 1.28B 103B | Capitalization | 261B 1.65B 132B |
|---|---|---|---|---|---|
| Net income 2024 * | 19.79B 125M 10B | Net income 2025 * | 19.91B 126M 10.06B | EV / Sales 2024 * | 1.53 x |
| Net Debt 2024 * | 34.69B 219M 17.54B | Net Debt 2025 * | 39.72B 251M 20.08B | EV / Sales 2025 * | 1.48 x |
| P/E ratio 2024 * |
13.2
x | P/E ratio 2025 * |
13.1
x | Employees | 3,393 |
| Yield 2024 * |
2.18% | Yield 2025 * |
2.31% | Free-Float | 0% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Mitsuo Sawai
CEO | Chief Executive Officer | 67 | 31/03/21 |
| President | 66 | 31/03/21 | |
Toru Terashima
BRD | Director/Board Member | 64 | 31/03/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mitsuo Sawai
CEO | Chief Executive Officer | 67 | 31/03/21 |
Kenzo Sawai
BRD | Director/Board Member | 55 | 31/03/21 |
Masatoshi Ohara
BRD | Director/Board Member | 73 | 31/03/21 |
Sawai Group Holdings Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of medical and over-the-counter drugs. The Company operates in two segments. The Japan segment is engaged in medical and healthcare-related businesses such as manufacture and sale of pharmaceuticals and medical devices, as well as various related businesses. The America segment is engaged in the sale of manufactured pharmaceutical products to wholesale stores in America. The company is also engaged in the research and development of pharmaceutical products.
Sector
Pharmaceuticals
Calendar
12/05/2024
- Q4 2023 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
